Oncolytics Biotech® announces collaboration with Merck and Northwestern University
Oncolytics announced an investigator sponsored study supported by Merck and Northwestern University. This study is an extension of the reported phase 1 study that will investigate pelareorep in combination with Merck’s anti-PD1 checkpoint inhibitor Keytruda®, to treat pancreatic cancer patients. May 17, 2018